|
DK1032671T3
(da)
*
|
1997-11-26 |
2004-10-11 |
Zymogenetics Inc |
Mammalt cytokin-lignende polypeptid-10
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
|
US7189400B2
(en)
|
1998-03-17 |
2007-03-13 |
Genetics Institute, Llc |
Methods of treatment with antagonists of MU-1
|
|
JP4741139B2
(ja)
|
1999-12-23 |
2011-08-03 |
ザイモジェネティクス， インコーポレイテッド |
可溶性インターロイキン−２０レセプター
|
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
|
US7122632B2
(en)
|
1999-12-23 |
2006-10-17 |
Zymogenetics, Inc. |
Soluble Interleukin-20 receptor
|
|
DE60043957D1
(de)
*
|
1999-12-23 |
2010-04-15 |
Zymogenetics Inc |
Verfahren zur Behandlung von Entzündungen
|
|
US20030023033A1
(en)
*
|
2001-07-26 |
2003-01-30 |
Laure Dumoutier |
Novel class II cytokine receptors and uses thereof
|
|
EP1337636B1
(en)
|
2000-08-08 |
2006-10-18 |
ZymoGenetics, Inc. |
Soluble zcytor 11 cytokine receptors
|
|
DE60121808T2
(de)
|
2000-09-15 |
2007-03-29 |
Zymogenetics, Inc., Seattle |
Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
|
|
KR100628425B1
(ko)
|
2001-06-20 |
2006-09-28 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
US20050272120A1
(en)
|
2001-06-20 |
2005-12-08 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
DK1432431T3
(en)
*
|
2001-10-04 |
2017-07-10 |
Genetics Inst Llc |
Methods and compositions for modulating interleukin-21 activity
|
|
WO2003051384A1
(en)
|
2001-12-17 |
2003-06-26 |
Zymogenetics, Inc. |
Method for treating cervical cancer
|
|
JPWO2003090779A1
(ja)
*
|
2002-04-25 |
2005-08-25 |
中外製薬株式会社 |
肺癌治療薬
|
|
KR20050116392A
(ko)
*
|
2003-03-24 |
2005-12-12 |
지모제넥틱스, 인코포레이티드 |
항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의사용 방법
|
|
JP2007501813A
(ja)
|
2003-08-08 |
2007-02-01 |
ノボ ノルディスク アクティーゼルスカブ |
新生血管形成と関連した症状を治療および診断するためのインターロイキン−２０
|
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
|
US7393684B2
(en)
*
|
2003-11-21 |
2008-07-01 |
Zymogenetics, Inc. |
Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies
|
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
|
BRPI0516975A
(pt)
|
2004-10-22 |
2008-09-30 |
Zymogenetics Inc |
anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
|
|
JP2011526591A
(ja)
|
2008-06-30 |
2011-10-13 |
ノボ・ノルデイスク・エー／エス |
抗ヒトインターロイキン−２０抗体
|
|
WO2010042634A1
(en)
*
|
2008-10-07 |
2010-04-15 |
National Cheng Kung University |
Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
|
|
US8454956B2
(en)
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
|
US8470980B2
(en)
|
2009-09-09 |
2013-06-25 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
CA2785139A1
(en)
|
2009-12-22 |
2011-06-30 |
Novartis Ag |
Tetravalent cd47-antibody constant region fusion protein for use in therapy
|
|
BR112012026213B1
(pt)
|
2010-04-15 |
2021-12-28 |
Medimmune Limited |
Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
|
|
WO2011156328A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
CN103313990B
(zh)
|
2010-11-17 |
2016-07-20 |
基因泰克公司 |
丙氨酰美登醇抗体偶联物
|
|
US8679767B2
(en)
|
2011-05-12 |
2014-03-25 |
Genentech, Inc. |
Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
|
|
MX2013014789A
(es)
|
2011-06-16 |
2014-01-20 |
Novartis Ag |
Proteinas solubles para utilizarse como productos terapeuticos.
|
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
|
SG11201401406YA
(en)
|
2011-10-14 |
2014-05-29 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2013117751A2
(en)
|
2012-02-10 |
2013-08-15 |
Novo Nordisk A/S |
Methods related to treatment of inflammatory diseases and disorders
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
WO2013164440A1
(en)
|
2012-05-03 |
2013-11-07 |
Novo Nordisk A/S |
Methods related to treatment of inflammatory diseases and disorders
|
|
WO2014015133A1
(en)
*
|
2012-07-19 |
2014-01-23 |
National Cheng Kung University |
Treatment of osteoarthritis using il-20 antagonists
|
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SMT201800346T1
(it)
|
2012-10-12 |
2018-09-13 |
Medimmune Ltd |
Coniugati pirrolobenzodiazepina-anticorpo
|
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
WO2014057074A1
(en)
|
2012-10-12 |
2014-04-17 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
PT2906298T
(pt)
|
2012-10-12 |
2018-12-28 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpos
|
|
SI2906253T1
(sl)
|
2012-10-12 |
2018-11-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin-protitelo proti PSMA
|
|
WO2014057122A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
|
|
CN110627797A
(zh)
|
2012-12-21 |
2019-12-31 |
麦迪穆有限责任公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
|
JP6307519B2
(ja)
|
2012-12-21 |
2018-04-04 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンおよびその結合体
|
|
JP6340019B2
(ja)
|
2013-03-13 |
2018-06-06 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
EP2968596B1
(en)
|
2013-03-13 |
2019-03-06 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2014230735B2
(en)
|
2013-03-13 |
2018-03-15 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US10442836B2
(en)
|
2013-08-12 |
2019-10-15 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2015052535A1
(en)
|
2013-10-11 |
2015-04-16 |
Spirogen Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
|
JP6980384B2
(ja)
|
2013-12-16 |
2021-12-15 |
ジェネンテック， インコーポレイテッド |
１−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
|
|
RU2689388C1
(ru)
|
2013-12-16 |
2019-05-28 |
Дженентек, Инк. |
Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
|
|
EA201691023A1
(ru)
|
2013-12-16 |
2016-10-31 |
Дженентек, Инк. |
Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
|
|
AU2015271709B2
(en)
|
2014-06-06 |
2020-11-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
JP6622293B2
(ja)
|
2014-09-12 |
2019-12-18 |
ジェネンテック， インコーポレイテッド |
アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
AU2015317653A1
(en)
|
2014-09-17 |
2017-04-06 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
|
TWI711630B
(zh)
|
2014-11-21 |
2020-12-01 |
美商必治妥美雅史谷比公司 |
抗ｃｄ７３抗體及其用途
|
|
HRP20201756T8
(hr)
|
2014-11-21 |
2021-08-20 |
Bristol-Myers Squibb Company |
Antitijela koja sadrže modificirane regije teškog lanca
|
|
US10780096B2
(en)
|
2014-11-25 |
2020-09-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
JP6752204B2
(ja)
|
2014-12-03 |
2020-09-09 |
ジェネンテック， インコーポレイテッド |
四級アミン化合物及びその抗体−薬物コンジュゲート
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
CA2988115A1
(en)
|
2015-06-03 |
2016-12-08 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
JP6983776B2
(ja)
|
2015-11-19 |
2021-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
ES2871001T3
(es)
|
2017-02-08 |
2021-10-28 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
WO2018192944A1
(en)
|
2017-04-18 |
2018-10-25 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
|
CA3057748A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
KR20200006115A
(ko)
|
2017-05-16 |
2020-01-17 |
브리스톨-마이어스 스큅 컴퍼니 |
항-gitr 효능제 항체에 의한 암의 치료
|
|
ES2988683T3
(es)
|
2017-06-14 |
2024-11-21 |
Adc Therapeutics Sa |
Pautas posológicas para la administración de un CAF anti-CD19
|
|
SG11202000358YA
(en)
|
2017-08-18 |
2020-02-27 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
KR20220156974A
(ko)
|
2017-09-20 |
2022-11-28 |
주식회사 피에이치파마 |
타일란스타틴 유사체
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
EP3870235A1
(en)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Conjugated chemical inducers of degradation and methods of use
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
MX2021010477A
(es)
|
2019-03-15 |
2021-10-01 |
Medimmune Ltd |
Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
US12409208B2
(en)
|
2019-10-28 |
2025-09-09 |
LBL Biotechnology Inc. |
Treating tissue fibrosis with interleukin 24
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
EP4637833A2
(en)
|
2022-12-23 |
2025-10-29 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
WO2024220546A2
(en)
|
2023-04-17 |
2024-10-24 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|